Burgdorf, Switzerland-based MyLife says it has now become the legal manufacturer for MyLife products, as of today, June 1, 2026. It plans to introduce products under the new legal manufacturer to the market in a step-by-step process beginning July 1, 2026.
This marks the latest step forward for the company, which completed its initial transition into an independent company after separating from Ypsomed at the beginning of this year.
In August 2025, Ypsomed announced that it completed the sale of its diabetes care business to TecMed AG. With this sale, the company transitioned MyLife from a business unit into a standalone company. This follows a recent medtech trend, with both BD (Embecta) and Medtronic (MiniMed) deciding to separate their diabetes businesses within the past few years.
MyLife says its new identity will be gradually introduced across markets, including with updated product and company names. It also plans to refresh packaging and labeling, build a new global website and update regulatory and legal manufacturer information.
Product name changes include transitioning MyLife Loop to MyLoop, MyLife YpsoPump to YpsoPump and MyLife YpsoPump Orbit infusion sets to MyOrbit.
“Our new identity reflects who we are today and what guides us going forward,” said Sébastien Delarive, CEO of MyLife Diabetes Care. “Driven by science, engineering and dedication, we develop solutions that support people living with diabetes in everyday life, while maintaining the quality, safety and continuity that healthcare professionals, partners and users know and trust.”
